Compare CYN & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYN | VNRX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 24.5M |
| IPO Year | 2021 | 2012 |
| Metric | CYN | VNRX |
|---|---|---|
| Price | $1.12 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 141.2K | ★ 539.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | $368,138.00 | ★ $1,727,384.00 |
| Revenue This Year | $3,359.28 | $355.66 |
| Revenue Next Year | $347.47 | $849.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $1.03 | $0.13 |
| 52 Week High | $6.82 | $3.26 |
| Indicator | CYN | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 22.24 |
| Support Level | $1.07 | $0.19 |
| Resistance Level | $1.40 | $0.91 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 36.00 | 0.07 |
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.